Clinical Trial Search

Primary: Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements — -2.09; 2.83; -1.92; -1.10 mg/dL

Primary: Time to Target — 3.7; 6.3 days

Primary: Time to Relapse in Each Treatment Condition. — 11.4; 6.3 weeks

Primary: Median Tolerability Score on 10-point Visual Analog Scale (VAS) — 7; 8; 8; 8 units on a scale

Primary: Change in Time Contacting Objects — 40.75 percentage of time — p=<.05

Primary: To Evaluate Safety and Tolerability of Infusions of BMN 110 at a Dose of 2.0 mg/kg/Week Over a 52-week Period in MPS IVA Subjects Less Than 5 Years of Age at Time of…

Primary: Histological Response Determined by FDG Uptake Correlates — 2; 3; 38 participants

Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants — 16.4 Percentage of participants — p=<0.001

Primary: The Number of Participants With Adverse Events as a Measure of Safety — 5; 5; 6; 20 Participants

Primary: Percentage of Participants Meeting American College of Rheumatology Response Criteria ≥20% (ACR20): Month 3 — 50.47; 60.58; 51.89; 33.33 Percentage or participants…

Primary: Number of Participants That Experienced a Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 participants

Primary: Percent Change From Baseline in Pain Score During Week 1 — 33.3 percent change

Primary: Number of Subjects With a Varicella Vaccine Response — 1 Participants

Primary: Change of Donor Specific Antibodies (DSA) — 35.7 percent change in DSAs

Primary: Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period. — 7.79; 8.41; 8.28; 6.16…